Delcath Systems (NASDAQ:DCTH) Announces Earnings Results

Delcath Systems (NASDAQ:DCTHGet Free Report) issued its earnings results on Tuesday. The company reported ($0.48) earnings per share for the quarter, topping the consensus estimate of ($0.67) by $0.19, RTT News reports. Delcath Systems had a negative return on equity of 563.60% and a negative net margin of 2,308.86%. The business had revenue of $0.54 million for the quarter, compared to analyst estimates of $0.48 million. During the same quarter last year, the company earned ($0.86) EPS.

Delcath Systems Trading Down 6.3 %

Shares of DCTH opened at $4.77 on Friday. Delcath Systems has a fifty-two week low of $2.25 and a fifty-two week high of $7.99. The firm has a 50-day simple moving average of $4.36 and a 200-day simple moving average of $3.85.

Insider Activity at Delcath Systems

In related news, Director Gil Aharon bought 26,882 shares of the stock in a transaction on Tuesday, March 19th. The shares were bought at an average cost of $3.72 per share, for a total transaction of $100,001.04. Following the purchase, the director now owns 1,069,710 shares of the company’s stock, valued at approximately $3,979,321.20. The acquisition was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 21.10% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Cibc World Market Inc. boosted its holdings in Delcath Systems by 4.0% in the 1st quarter. Cibc World Market Inc. now owns 88,751 shares of the company’s stock valued at $568,000 after purchasing an additional 3,432 shares in the last quarter. Dimensional Fund Advisors LP purchased a new position in Delcath Systems in the first quarter worth $75,000. Vanguard Group Inc. lifted its holdings in Delcath Systems by 5.7% in the first quarter. Vanguard Group Inc. now owns 360,900 shares of the company’s stock valued at $2,309,000 after acquiring an additional 19,605 shares during the period. Millennium Management LLC purchased a new stake in shares of Delcath Systems during the 2nd quarter worth $40,000. Finally, Tower Research Capital LLC TRC increased its holdings in shares of Delcath Systems by 107.8% in the 1st quarter. Tower Research Capital LLC TRC now owns 4,663 shares of the company’s stock valued at $26,000 after purchasing an additional 2,419 shares in the last quarter. 61.12% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on DCTH shares. StockNews.com upgraded shares of Delcath Systems to a “sell” rating in a research note on Wednesday. HC Wainwright lifted their target price on Delcath Systems from $18.00 to $20.00 and gave the stock a “buy” rating in a research report on Wednesday. One equities research analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $18.50.

View Our Latest Report on DCTH

Delcath Systems Company Profile

(Get Free Report)

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.

Read More

Earnings History for Delcath Systems (NASDAQ:DCTH)

Receive News & Ratings for Delcath Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Delcath Systems and related companies with MarketBeat.com's FREE daily email newsletter.